Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) SIG Poster Highlights
Nov
2026
Description
Join us for a poster highlight of the top abstracts from the Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) SIG.
Presentations
1:30 PM
- 1:33 PM
Convention Center - Summit 1, The Park @TLM, Hall D
Welcome & Introductions
Robert J. Fontana, MD, FAASLD | Moderator
1:33 PM
- 1:38 PM
Convention Center - Summit 1, The Park @TLM, Hall D
Early and week 52 biomarker (MRI-PDFF, ALT, MRE and PRO-C3) responses to resmetirom predict improvements in MASH and liver fibrosis
Rohit Loomba, MD, MHSc, FAASLD | Presenter
1:38 PM
- 1:43 PM
Convention Center - Summit 1, The Park @TLM, Hall D
Efficacy of survodutide treatment assessed by liver endpoints across weight-reduction category at end of treatment: results from a phase 2 trial of survodutide in people with metabolic dysfunction-associated steatohepatitis and fibrosis
Arun Sanyal | Presenter
1:43 PM
- 1:48 PM
Convention Center - Summit 1, The Park @TLM, Hall D
Beyond Alcohol Self-Report: Phosphatidylethanol (PEth) Assessment Uncovers Clinically Significant Alcohol Exposure in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Zobair M Younossi, MD, MPH, FAASLD | Presenter
1:48 PM
- 2:00 PM
Convention Center - Summit 1, The Park @TLM, Hall D
Q&A & Closing
Amreen Dinani, MD FRCPC | Moderator
